

Emboline receives U.S. allowance for key piece of its seminal patent portfolio of aortic embolic protection technologies for percutaneous heart valve procedures such as TAVR

FREMONT, Calif.--([BUSINESS WIRE](#) [1])--Emboline, Inc., an emerging medical device company, has received Notice of Allowance from the United States Patent and Trademark Office (USPTO) related to its aortic embolic protection devices for percutaneous heart valve repair and replacement. The Company is initially focused on developing its novel Emboline CAP™ device: a game-changing, next-generation system intended to provide complete protection of the arterial bed (both the cerebrals and the aortic lumen) utilizing a uniquely ported design that maintains tool access through the filter. In addition, Emboline is also developing Emboliner™, a simple-to-use system for protection of the cerebral vessels alone. Embolines technologies are derived from intellectual property invented by Amir Belson, M.D., founder of Neoguide Systems, a company that developed platform technology for minimally invasive surgical procedures and was acquired by Intuitive Surgical in 2009.

"Our emergence is timely, given the significant attention on transcatheter aortic valve replacement at this month's TCT 2011 conference," said Scott Russell, Embolines General Manager. "For these exciting new TAVR procedures to realize their clinical potential, the risk of stroke must be rigorously managed. Our technology is designed not only to eliminate the risk of embolic stroke from TAVR procedures, but it is also the only technology designed to simultaneously shield the aortic lumen in order to protect the rest of the arterial bed as well. No doubt, allowance of this patent fortifies the competitive advantage of our IP portfolio and is a critically important milestone in our comprehensive strategy for device development in the aortic embolic-protection space."

Emboline is working toward an acute preclinical proof-of-concept of its technology, targeted by Q1 2012. The proof-of-concept development is being done in partnership with NDC (Fremont, Calif.), SeptRx, Inc. (Fremont, Calif.) and US BioDesign (Perkasie, Penn.).

CLINICAL NEED

Cerebral embolism is a known complication of cardiac surgery, cardiopulmonary bypass and catheter-based interventional cardiology and electrophysiology procedures. Embolic particles, which may include thrombus, atheroma and lipids, may become dislodged by surgical or catheter manipulations and enter the bloodstream. Cerebral embolism can lead to neuropsychological deficits, stroke and even death. Other organs downstream can also be damaged by embolism, resulting in diminished function or organ failure. Prevention of such embolism would benefit patients and improve the outcome of these procedures. These risks are especially

Emboline receives U.S. allowance for key piece of its seminal patent portfolio

Published on Medical Design Technology (<http://www.mdtmag.com>)

critical in transcatheter aortic valve replacement (TAVR). Stroke rates related to TAVR have been recorded at between four and 20 percent. During catheter delivery and valve implantation, plaque may be dislodged from the vasculature and may travel through the carotid circulation and into the brain. The adoption and growth of TAVR procedures may be stifled until a reliable, simple-to-use embolic protection system exists to improve the safety of these procedures.

For further information about Embolines technologies, please contact Scott Russell (General Manager) at srussell@emboline.com [2], 510/225-9258, x1.

Posted by Sean Fenske, Editor-in-Chief, MDT

Source URL (retrieved on 01/30/2015 - 2:36pm):

<http://www.mdtmag.com/news/2011/12/emboline-receives-us-allowance-key-piece-its-seminal-patent-portfolio-aortic-embolic-protection-technologies-percutaneous-heart-valve-procedures-such-tavr>

Links:

[1] <http://www.businesswire.com/>

[2] <mailto:srussell@emboline.com>